Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has exercised its first contract option valued at $261 million to procure doses of AV7909 (anthrax vaccine adsorbed with adjuvant) for delivery into the Strategic National Stockpile (SNS) over 12 months. This contract option was exercised under the company’s 2016 development and procurement contract with BARDA, valued at up to $1.5 billion, that includes a five-year base period of performance to develop AV7909 for post-exposure prophylaxis of anthrax disease and to deliver an initial three million doses to the SNS, as well as contract options for procurement of up to an additional 50 million doses. This exercise of the contract option through a modification is the first such option for procurement of doses to follow the initial deliveries of doses under the base contract.
Anne Lindblad, PhD, joined Emmes in 1982 as a Biostatistician and currently serves as the President and CEO of the company. She has supported clinical research throughout her career, serving as Principal Investigator of projects spanning diverse disease areas, including neurology, ophthalmology, oncology, dialysis, transplantation, speech and hearing, and dentistry.
What’s it like having two high-profile jobs at once? Ask Brian Darmody, who’s been serving the University of Maryland College Park (UMCP) since 1982 and long ago ascended to the position of associate vice president. Darmody recently accepted a new position as CEO with the Association of University Research Park (AURP), which will keep him in the local focus as he works toward retiring from UMCP at the end of 2019 – while continuing to work out of the Discovery District at UMCP and pursue new challenges.
The gene therapy company has made three distinct moves over the past week that reinforce its intention to get products to market after a decade in business.
Precision for Medicine, part of Precision Medicine Group, announced it has acquired leading biospecimen providers ProMedDx and GLAS, significantly expanding its capabilities and expertise in the biospecimen solutions space. With the acquisitions, Precision now offers an unmatched level of scientific understanding, high-quality specimen solutions, and global scale.
A venture capital firm formed by a founder of one of the first companies to win Food and Drug Administration approval for a cell therapy for cancer closed a new fund worth more than half of $1 billion.
Magenta Medical, the heart failure solutions developer based on proprietary miniaturized blood pump technology announced they have raised funds Monday in a round led by global venture capital firm New Enterprise Associates (NEA.)
The University System of Maryland (USM) has named Claire Broido Johnson, MBA, as Managing Director of the Maryland Momentum Fund (MMF), a $10 million investment fund that supports early-stage companies affiliated with USM institutions. She joins the USM this week.
gel-e is developing a line of advanced hemostatic and wound treatment products that address unmet needs from the operating room to the backyard. Following previous clearances for topical and external use of its platform technology (see http://www.gel-e.co/news.html), the Company is now expanding its label to include use for internal and surgical applications. The first product, now on an accelerated path as a Breakthrough Device, is an expanding injectable hemostat, Life Foam™. Life Foam can rapidly provide temporary control of bleeding from non-compressible abdominal wounds that are not amenable to tourniquet application in trauma and battlefield conditions. As the tradename suggests, this product is designed to save the lives of those injured in battle, or that are the victims of traumatic accidents or even terrorist attacks.
The U.S. Economic Development Administration awarded more than $600,000 to a division of Johns Hopkins University on Tuesday to increase economic development in the region’s digital health field.
Canton-based VitusVet, which built a health IT platform for vets, received investment from Nationwide Insurance as the company’s team continues to grow.
County Executive Marc Elrich and Council Vice President Sidney Katz are embarking on a multi-pronged joint initiative: 4Business – Benchmarking to Be the Best for Business.
The objective is to engage the local business community in a grassroots campaign to assist businesses to locate, grow and prosper in Montgomery County.
Montgomery County Economic Development Corporation – Maryland is excited to be attending Site Selectors Guild Fall Forum this September 9-11th in Dallas! We’re looking forward to connecting with Guild members to tell them about all the great business assets Montgomery County has to offer! hashtag#SSG hashtag#econdev hashtag#siteselection hashtag#Dallas
The Johns Hopkins Hospital is once again ranked #3 in the nation out of more than 4,600 hospitals reviewed for U.S. News & World Report’s 2019–20 Best Hospitals list, which was released today.
GlaxoSmithKline and Pfizer have finally closed on a multibillion-dollar merger that combined their consumer healthcare businesses, creating the world’s largest over-the-counter business.
The pharmaceutical giants — which own household names like Advil and Tums — announced the joint venture back in December 2018.
You might have lost count of how many times Roche has extended the tender offer period for shares of Spark Therapeutics. As of Wednesday, it’s five. And once again, regulatory delays are part of the problem.
Was your credit card unexpectedly rejected? Or have you spotted unfamiliar charges on your bank statement? These are just a couple signs of potential identity theft. (Source: Federal Trade Commission)
Once you realize your identity has been compromised, you need to act fast. But don’t panic; this guide will walk you through each step you need to take to be sure you recover as quickly as possible.
Mayo Clinic and medical device giant Boston Scientific are slated to announce a new med-tech accelerator Monday.
The collaboration will be located in One Discovery Square, a new building in Rochester adjacent to Mayo Clinic that’s meant to attract medical technology startups.
